Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of seltorexant monotherapy in adults and older adults with major depressive disorder, with open-label long-term extension
CTR20263299Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of seltorexant in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started May 2026; status: active.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20263299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263299.